Invanz 1gm Injection contains Ertapenem, a broad-spectrum carbapenem antibiotic indicated for the treatment of moderate to severe bacterial infections caused by susceptible organisms. Ertapenem exhibits potent bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins. It is effective against a wide range of gram-positive and gram-negative aerobic and anaerobic pathogens, including those responsible for complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired pneumonia, acute pelvic infections, and complicated urinary tract infections. Invanz 1gm Injection is administered via intravenous or intramuscular routes, providing convenient once-daily dosing due to its prolonged half-life. The medication should be reconstituted and diluted according to prescribing information to ensure appropriate administration. Caution is advised in patients with a history of hypersensitivity to beta-lactam antibiotics. Dose adjustment may be necessary in individuals with renal impairment. Common adverse reactions include injection site reactions, diarrhea, nausea, and headache. Invanz 1gm Injection should be used under strict medical supervision with appropriate microbiological monitoring to prevent the development of drug resistance. It is contraindicated in patients with known hypersensitivity to Ertapenem or other carbapenems.